Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Neurosciences
Immunomodulatory Effects Of Novel Therapies For Stroke, Aaron A. Hall
Immunomodulatory Effects Of Novel Therapies For Stroke, Aaron A. Hall
USF Tampa Graduate Theses and Dissertations
Each year, approximately 795,000 people suffer a new or recurrent stroke. About 610,000 of these are first attacks, and 185,000 are recurrent attacks (Carandang et al. 2006). Currently the only FDA approved treatment for ischemic stroke is recombinant tissue plasminogen activator (Alteplase) (Marler and Goldstein 2003). Unfortunately its use is restricted to a short, 4.5 hour, time window. Two promising therapies in the treatment of stroke at delayed timepoints are human umbilical cord blood cells (HUCBC) and the sigma receptor agonist DTG
The first series of experiments were conducted to characterize the effects of sigma receptors on various aspects of …
Alternative Targets For The Treatment Of Stroke, Craig T. Ajmo Jr.
Alternative Targets For The Treatment Of Stroke, Craig T. Ajmo Jr.
USF Tampa Graduate Theses and Dissertations
Stroke is cerebrovascular injury that has been reported to be the third leading cause of death and the first leading cause of disability in the world (W. H.O. 2007). Currently, there is only one FDA approved treatment for stroke which is recombinant tissue plasminogen activator. This treatment has a narrow therapeutic window of three hours after ischemic stroke and can adversely cause the production of oxygen free radicals and intracranial hemorrhage. These limitations result in only 2-3% of all stroke victims as being candidates for this therapy as many patients do not arrive at the hospital in time to receive …